IQVIA Holdings Inc. (NYSE:IQV) Holdings Cut by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,857 shares of the medical research company’s stock after selling 862 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IQVIA were worth $954,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC acquired a new stake in IQVIA in the fourth quarter worth $33,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the 4th quarter worth about $44,000. Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Versant Capital Management Inc boosted its stake in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA in the 4th quarter worth about $60,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. Truist Financial reiterated a “buy” rating and set a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, Barclays dropped their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Performance

Shares of NYSE IQV opened at $179.40 on Friday. IQVIA Holdings Inc. has a 52-week low of $176.74 and a 52-week high of $253.84. The stock’s fifty day simple moving average is $193.55 and its 200 day simple moving average is $206.91. The stock has a market capitalization of $31.63 billion, a price-to-earnings ratio of 23.92, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.